RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Retatrutide is a single investigational molecule that activates GIP, GLP-1 and glucagon receptors. Its clinical research includes studies of body weight, metabolic disease and liver fat. Published phase 3 reports in September 2026 substantially expanded the earlier evidence. This overview reviews four publications while separating trial populations, measurement methods and outcomes. The findings concern controlled clinical research, not the suitability of independently supplied research materials for personal use. [1–4]
WHAT TRIPLE AGONISM MEANS
A receptor agonist activates a biological signaling target. Retatrutide combines activity at three receptor types in one molecule; it is not simply a mixture of three separate peptides. The research question is whether this combination can produce useful effects with an acceptable safety profile under controlled conditions. [1]
The number of targets alone does not establish superiority. Comparing compounds requires comparable clinical evidence, ideally a direct randomized comparison. It also requires considering adverse effects and study design alongside the size of a reported change.
THE PHASE 2 OBESITY STUDY
Jastreboff and colleagues reported a randomized, placebo-controlled trial involving 338 adults in 2023. At 48 weeks, the highest-exposure group had an estimated mean body-weight reduction of 24.2%, compared with 2.1% in the placebo group. These were group averages, not outcomes guaranteed for each participant. [1]
Gastrointestinal adverse events were the most common and were generally mild or moderate. The investigators also observed increases in heart rate that peaked earlier in follow-up and later declined. The study provided an important development signal, but its size and duration limited conclusions about uncommon events and longer-term outcomes. [1]
PHASE 3 RESEARCH WITHOUT DIABETES
The TRIUMPH-1 report, published online in September 2026, randomized 2,339 adults with obesity without diabetes. The trial followed participants for 80 weeks. Its treatment-regimen analysis estimated mean weight reductions ranging from 17.6% to 25.0% across retatrutide groups, compared with 3.9% with placebo. [2]
The study also assessed defined subgroups with knee osteoarthritis or obstructive sleep apnea and reported improvements in their respective pain and breathing-event outcomes. Gastrointestinal events were the most common adverse events. Those subgroup findings should remain attached to the conditions and measures actually studied. [2]
An analysis that estimates outcomes regardless of treatment interruptions can produce a different percentage from an analysis assuming continued treatment. Readers should therefore check the analysis behind a headline rather than combining the largest number from one report with the population or timeframe of another.
PHASE 3 RESEARCH WITH TYPE 2 DIABETES
Bellido and colleagues reported TRIUMPH-2 in 2026. This randomized, placebo-controlled trial enrolled 1,152 adults with type 2 diabetes and overweight or obesity. At 80 weeks, its treatment-regimen analysis estimated mean weight reductions of 11.9%, 16.8% and 18.8% across the retatrutide groups, versus 5.1% with placebo. [3]
Diarrhea and nausea were more common with retatrutide. The participants' diabetes and background treatment distinguish this study from TRIUMPH-1. Differences between the trials should not be interpreted as a direct experiment proving why one population responded differently. Eli Lilly funded the development trials discussed here. [1–3]
WHAT THE LIVER-FAT SUBSTUDY SHOWED
Sanyal and colleagues reported a 98-participant substudy in 2024 involving elevated liver fat. At 24 weeks, the highest retatrutide group had an estimated relative liver-fat reduction of 82.4%, compared with a 0.3% increase with placebo. Liver fat was assessed with imaging. [4]
That percentage refers to change relative to baseline liver fat; it is not a percentage reduction in total body weight. Nor does an imaging improvement alone establish reversal of liver fibrosis or prevention of liver failure. The substudy came from the phase 2 program and should not be counted as a wholly independent large trial.
WHAT THE EVIDENCE CAN SUPPORT
These studies document a substantial clinical development program, but each result has boundaries. Longer observation, adverse-event assessment and direct comparisons remain distinct questions. Statistical significance does not remove those boundaries or verify a separate product's identity, composition or quality.
Research-use-only materials require their own analytical documentation and remain restricted to qualified laboratory work. Clinical publications provide an educational evidence record; they do not authorize personal experimentation or establish equivalence between a laboratory vial and the study product.
REFERENCES
1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526.
https://doi.org/10.1056/NEJMoa2301972
2. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published online September 29, 2026.
https://doi.org/10.1056/NEJMoa2604169
3. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408:1455–1472.
https://doi.org/10.1016/S0140-6736(26)01861-1
4. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048.
https://doi.org/10.1038/s41591-024-03018-2